 Connection
Megan Rech to Factor Xa Inhibitors
This is a "connection" page, showing publications Megan Rech has written about Factor Xa Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.016 |
|
|
|
-
Markovic N, Budde E, Evans CT, Finch D, Xia Y, Huo Z, Han JH, Rech MA. Time to hemostatic agent administration increases mortality in veterans with factor Xa inhibitor-related intracranial hemorrhage. Am J Emerg Med. 2025 12; 98:201-206.
Score: 0.787
-
Rech MA, Budde E, Evans CT, Finch D, Xia Y, Huo Z, Han JH. Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans. Am J Emerg Med. 2025 11; 97:97-102.
Score: 0.782
-
Rech MA, Gottlieb M. Prothrombin Complex Concentrate Should Be Used to Reverse Factor Xa Inhibitors in the Setting of Life-Threatening Bleeding. Ann Emerg Med. 2023 09; 82(3):362-363.
Score: 0.658
-
Rech MA, Masic D, Hammond DA. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding. West J Emerg Med. 2021 Feb 26; 22(2):163-169.
Score: 0.577
-
Cotiguala L, Przybylski A, Linberger L, Brokhof M, Kenyon N, Joyce C, Dierker M, Ferguson K, Rech MA, Trotter C, Aguirre O, Lopez-Soler RI. Apixaban Use Before Kidney Transplantation: Is Reversal Necessary? Pharmacotherapy. 2026 Oct; 46(10):e70200.
Score: 0.213
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|